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Summary 
In a phase II study, 27 patients with metastatic breast cancer were treated with oral etoposide as second-line 
chemotherapy at a dose of 50 mg/m2/day for 21 days, which courses were repeated every 4 weeks. Twenty-one 
patients were evaluable for response, and twenty-five for toxicity. In two (10%) patients apartial response was 
observed with a duration of 60 and 122 weeks respectively, and seven patients (33%) showed stable disease. 
Gastrointestinal toxicity was usually mild, though relatively frequent. Anemia grade II and III was observed 
in 20 % of all courses (< 10% of all measurements), and leukopenia grade III and IV was observed in 22 % of all 
courses (< 10% of all measurements). There was one toxic death. 
Reviewing the literature we calculated a response rate of intravenous etoposide treatment of 8% in 276 
patients with metastatic breast cancer from 7 studies (response rates ranging between 0-14%), while (chronic) 
oral treatment caused aresponse rate of 19% in 145 patients from 8 different studies (response rates ranging 
between 0-35%). 
Introduction 
The prognosis of patients with disseminated breast 
cancer efractory to or relapsing from first-line che- 
motherapy is poor. All currently applied cytotoxic 
drugs yield low response rates (10-30%) with a 
median duration of response of about 6 months or 
less and frequently considerable toxicity [1]. There- 
fore, new approaches are warranted. Because 
breast cancers contain usually a relatively low per- 
centage of proliferating cells within the cell cycle, 
prolonged exposure to a cytotoxic drug is theoret- 
ically attractive. 
Etoposide (VP16-213), a semisynthetic podo- 
phyllotoxin derivative with a wide antitumor activ- 
ity, is a cell cycle phase-specific drug acting in the 
late S- and early G2-phase of the cell cycle with 
schedule dependency [2]. Activity of the drug is 
probably more lated to duration of exposure to 
tumor cells rather than to the area under the curve 
(AUC) [3-5]. Etoposide has been used in clinical 
trials for approximately 20 years without clear effi- 
cacy in breast cancer, but recently there is renewed 
interest in this drug because of the application of
new treatment schedules [6, 7]. There is clinical evi- 
dence that chronic daily administration oforal eto- 
poside can induce responses inpatients with differ- 
ent chemotherapy refractory solid tumors [8, 9]. 
Out of the four breast cancer patients in a phase I 
trial using prolonged low-dose oral etoposide [8], 
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one had an objective response and one patient with 
non-measurable disease had a subjective response. 
Based on these data we initiated a phase II study 
with daily oral administration of etoposide as sec- 
ond-line chemotherapy in patients with metastatic 
breast cancer. 
Patients and methods 
Eligibility criteria of this study included patients 
with measurable or evaluable lesions, age less than 
80 years, World Health Organization (WHO) per- 
formance score (PS) 2 or less, life expectancy of 
more than 2 months, serum bilirubin less than 
20 gmol/1, WBC above 3.0 x 109/1, platelets above 
100 x 109/1, no prior therapy with etoposide. Patients 
with a history of recent cardiac disease, or patients 
with metastases in the central nervous ystem, were 
excluded. Metastatic disease of all patients was con- 
sidered resistant to previous endocrine therapy and 
to first-line chemotherapy. All patients gave oral in- 
formed consent before entering the study. 
On-study evaluation consisted of medical history, 
physical examination, tumor measurements, com- 
plete blood count (Hb, WBC, platelets), automated 
blood chemistry, bonescan, bone and chest X-rays, 
and CT-scan or ultrasound of the liver in case of liv- 
er metastases. On follow-up complete blood count 
was performed weekly and response valuation was 
performed after every second course. 
Treatment consisted of etoposide 50 mg/m2/day, 
orally for three consecutive weeks, in a twenty- 
eight day cycle. Responses and toxicity were de- 
fined according to WHO criteria. Duration of com- 
plete and partial response was measured from ini- 
tiation of therapy till time of tumor progression. 
Results 
Twenty-seven patients entered the study. Patient 
characteristics are indicated in Table 1. Two of the 
27 patients were ineligible (PS: 3 and bilirubin 
43 gmol/1). All 25 eligible patients were evaluable 
for toxicity. The total number of courses of etopo- 
side administered was 90 (mean: 3.6; median 2, 
range 1-25). Gastrointestinal toxicity was usually 
mild. Twenty-two patients had no or only mild com- 
plaints of nausea (WHO grade 0-1), while four pa- 
tients (16%) experienced nausea and vomiting 
grade II-III, for which reason one of them was hos- 
pitalized. Alopecia was often related to previous 
chemotherapy, while in three patients the first hair 
loss (grade II-III) was undoubtedly etoposide-in- 
duced. Leukopenia grade III and IV occurred in 15 
patients (60%), in 22% of all courses, and in < 10% 
of all measurements; anemia grade II and III was 
observed in 9 patients (36%), in 20% of all courses, 
and in < 10% of all measurements. Mild to moder- 
ate thrombocytopenia w s infrequent (grade I-II: in 
3 % of all measurements). One patient died during 
the leukopenic period. 
Four of the 25 eligible patients were not evalua- 
ble for response because of early withdrawal (with- 
in the first 3 weeks). Reasons to stop the treatment 
Table 1. Patient characteristics 
Number of patients entered 27 
Number of eligible patients 25 
Number of patients evaluable 
for response 21 
for toxicity 25 
Age 
median (range) 
WHO performance status 
median (range) 
No of organ systems involved 
median (range) 
Time from first sign of metastatic disease to start of 
etoposide (months) 
median (range) 19 
No of prior hormonal therapies 
median (range) 1 
Prior chemotherapy 
Adjuvant 7 
Chemotherapy for metastatic disease 27 
Cyclophosphamide/Methotrexate/Flurouraci118 
Cyclophosphamide/D oxorubicin/Fluor uracil 8 
Cyclophosphamide/Epirubicin/Fluorouracil 1 
Site of metastatic lesion 
liver 10 
lung 7 
pleura 6 
bone 17 
lymph node 5 
skin 11 
breast 6 
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Fig. 1. Median survival time. 
in these 4 patients were: severe nausea nd vomit- 
ing (1), analysis of polyuria (1), anemia (1), and sud- 
den death in a patient with an axillary thrombosis 
two weeks after start of therapy. No complete re- 
sponses were observed in 21 patients evaluable for 
response. Two patients (10%) (95% confidence in- 
terval 1-30 %) achieved a partial response with a du- 
ration of 60 and 122 weeks, respectively. The first 
responding patient was treated before with hor- 
monal therapy for 3 months without success, fol- 
lowed by 12 courses of FEC chemotherapy with sta- 
bilisation of the disease. During etoposide treat- 
ment the lytic bone metastases showed fair sclero- 
sis. The second patient had been treated for three 
years with two lines of endocrine therapy, followed 
by 23 courses of CMF chemotherapy with a partial 
response. During etoposide therapy the pulmonary 
lesions showed a partial response and the bone le- 
sions remained stable. 
Seven patients (33%) had stable disease with a 
median duration of 19 weeks (range 9+-32 weeks). 
Progressive disease from the start of treatment was 
observed in twelve patients. For the 21 evaluable 
patients the median time to progression was 2 
months (mean: 4.3 months) and the median survival 
time was 8.3 months (mean: 11.3 months) (Fig. 1). 
Discussion 
Treatment results of second-line chemotherapy in 
metastatic breast cancer are disappointing and re- 
missions are usually of short duration [1]. There- 
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fore, testing of new treatment modalities remains of 
utmost importance. 
In the past twenty years etoposide has been ex- 
tensively used in the treatment of patients with a 
variety of solid tumors. Most experience with eto- 
poside in breast cancer is obtained with intravenous 
(i.v.) treatment schedules. Table 2 summarizes the 
treatment results with etoposide in this disease. 
Seven studies (concerning 276 patients) applied i.v: 
etoposide as a single agent in previously treated pa- 
tients. Response percentages varied from 0-14%, 
with an overall response rate of only 8% [10-16]. 
Table 2. Etoposide as _> second-line single agent herapy in meta- 
static breast cancer 
Treatment schedule No. of Response Ref. 
eval. pts (CR + PR) 
n % 
Intravenous administration 
100-250 mg/m zq every week 14 0 0 i0 
45 mg/m 2days 1-5 q 3 wk 60 3 5 11 
75 mg/m 2days 1-5 q 3 wk 59 5 8 
50-70 mg/m 2days 1-5 q 3 wk 35 5 14 12 
50-70 mg/m 2CI days 1-5 q 3 wk 31 4 13 
60-135 mg/m 2twice weekly 24 1 4 13 
125 mg/m 2days 1, 3, 5 q 3-4 wk 19 0 0 14 
100-125 mg/m z days 1, 3, 5 q 4-5 wk 19 2 11 15 
300-450 mg/m z days 1-3 q 4 wk 15 1 7 16 
Total 276 21 8 
Treatment schedule No. of Response Ref. 
eval. pts (CR + PR) 
n % 
Oral administration 
75-125 mg/m 2days 1-5 q 3 wk 14 0 0 10 
200 rag/day days 1-5 q 2-3 wk or 20 0 0 17 
300400 mg/day days 1-5 q 2 wk 
50 mg/m2/day; days 1-21 q 4 wk 4 1 25 8 
50 mg/m2/day; days 1-21 q 4 wk 18 4 22 18 
50 mg/mZ/day; days 1-21 q 4 wk 43 15 35 19 
50 rag/day; days 1-14 q 4 wk 10 1 10 20 
50 mg/mZ/day; days 1-21 q 4 wk 25 5 25 21 
50 mg/mZ/day; days 1-21 q 4 wk 21 2 10 This 
study 
Total 145 28 19 
CI = continuous infusion. 
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Thus these short-term intravenous schemes of sec- 
ond-line chemotherapy with etoposide have shown 
only moderate activity in breast cancer, while toxic- 
ity was generally considered acceptable with mye- 
losuppression emerging as the most frequent side 
effect. 
Treatment results of eight studies (including our 
study) using oral etoposide as second-line chemo- 
therapy in metastatic breast cancer are also shown 
in Table 2 [8,10,17-21]. In the studies of Cavalli et al. 
[10] and Falkson et al. [17] using a high dose oral re- 
gimen for five days no responses were observed. 
However, because the cytotoxic effect of etoposide 
is more related to the duration of tumor cell expo- 
sure to the drug rather than to the AUC, prolonged 
exposure might theoretically result in an augment- 
ed anti-tumor effect [3-5]. In a phase I trial [8] one 
out of 4 patients with breast cancer esponded to a 
long-term low-dose toposide regimen. The recom- 
mended dose for following phase II studies was 
therefore 50 mg/m2/day for 21 days in a 28 day cycle. 
We performed a phase II study using this regimen 
but achieved only 10% remissions. Palombo et al. 
[18], Martin et al. [19], and Atienza et al. [21] per- 
formed similar studies in breast cancer patients pre- 
treated with chemotherapy. They reported higher 
response rates, i.e. 22%, 35 % and 25 %, respectively 
(Table 2). On the other hand Calvert et al. [20] re- 
ported the same response rate of 10% in a subgroup 
of 10 patients treated with 50 mg etoposide per day 
after previous chemotherapy. In this heterogeneous 
study higher esponse rates were observed in a sub- 
group of chemotherapy naive patients (45% re- 
sponse) and at a higher dose (100 mg/day) regimen 
(35 % response, regarding mainly patients not treat- 
ed with chemotherapy before). When taking to- 
gether all literature data, (chronic) oral etoposide 
treatment caused an objective response in 19% of 
145 patients (Table 2) [8, 10, 17-21], mostly of short 
duration. Responses can occur in all types of meta- 
static sites. The toxicity observed in our study is 
comparable with those of other studies with leuco- 
penia as the most serious ide effect. Also Calvert et 
al. [20] and Atienza et al. [21] reported the occur- 
rence of toxic deaths, although this outpatient re- 
gimen appeared to be quite manageable. 
In conclusion, second-line chemotherapy with 
etoposide has only moderate activity in patients 
with metastatic disease in the presence of signifi- 
cant but manageable toxicity. Newer agents uch as 
taxol and taxotere might therefore be of greater in- 
terest [22, 23], but maybe etoposide can be of 
greater value in combination with these or other ac- 
tive agents. 
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